Prostate Cancer (CRPC)
7
4
5
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Comparison of Peak Expiratory Flow Changes After Robot-Assisted Versus Open Radical Prostatectomy
Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity
Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
Study on Human Bioequivalence of Triprerelin Acetate for Injection
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors